A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

NCT07464314
clinicaltrials.gov
Phase
Phase 1
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Participants
225
clinicaltrials.gov
Lead sponsor
GlaxoSmithKline
clinicaltrials.gov
Start date
2026-03-09
clinicaltrials.gov
Number of sites
12
clinicaltrials.gov

Summary
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.
clinicaltrials.gov
Short title
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
clinicaltrials.gov
Official title
A Phase 1, Observer-Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of an Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
clinicaltrials.gov

Control arm
Active comparator
clinicaltrials.gov
Registry reports results
No
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Phase
Phase 1
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov

Completion date
2027-06-03
clinicaltrials.gov
First posted
2026-03-11
clinicaltrials.gov
Registry last updated
2026-06-30
clinicaltrials.gov
Primary completion date
2026-12-03
clinicaltrials.gov
Start date
2026-03-09
clinicaltrials.gov

Participants
225
clinicaltrials.gov
Participant count basis
Estimated
clinicaltrials.gov
Planned participants
225
clinicaltrials.gov
Protocol amendments
2
clinicaltrials.gov
Number of sites
12
clinicaltrials.gov

Data monitoring committee
Yes
clinicaltrials.gov
Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
GlaxoSmithKline
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT07464314
clinicaltrials.gov
ClinicalTrials.gov ID
NCT07464314
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Randomised
Model
Sequential
Purpose
Prevention
Masking
Triple masking
Masking description
This is an observer-blind study.
Masked roles
Participants, Investigators, Outcome assessors
Sources for study design
clinicaltrials.gov

  1. Number of Participants with an Increase in Toxicity Grade of Laboratory Value Abnormalities Following Administration of the Study Intervention

    Timeframe: Day 1 to Day 3

    The assessed toxicity grades for laboratory value abnormalities will be defined as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Potentially life-threatening.

  2. Number of Participants with an Increase in Toxicity Grade of Laboratory Value Abnormalities following Administration of Study Intervention

    Timeframe: Day 1 to Day 8

  3. Number of Participants with an Increase in Toxicity Grade of Laboratory Value Abnormalities following Administration of Study Intervention

    Timeframe: Day 1 to Day 29

  4. Number of Participants with Solicited Administration Site Adverse Events (AEs)

    Timeframe: Day 1 to Day 7

    The solicited administration site AEs considered are pain, redness, swelling and lymphadenopathy.

  5. Number of Participants with Solicited Systemic AEs

    Timeframe: Day 1 to Day 7

    The solicited systemic AEs considered are fever, headache, fatigue, myalgia, arthralgia and chills.

  6. Number of Participants with Unsolicited AEs

    Timeframe: Day 1 to Day 28

    An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.

  7. Number of Participants with Serious Adverse Events (SAEs)

    Timeframe: Day 1 to Day 181

    A SAE is an AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or other situations that are considered serious per medical or scientific judgment.

  8. Number of Participants with Adverse Events of Special Interest (AESIs)

    Timeframe: Day 1 to Day 181

    The following events are considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, Aminotransferase elevation; myocarditis/pericarditis within 6 weeks after study intervention administration and potential immune-mediated diseases (pIMDs).

  9. Number of Participants with Medically Attended Adverse Events (MAAEs)

    Timeframe: Day 1 to Day 181

    A MAAE is an AE for which the participant received medical attention including any symptom or illness requiring hospitalization, or an emergency room visit, or visit to/by a healthcare professional.

  1. Geometric Mean Titer (GMT) Of Antigen 1 Titer

    Timeframe: At Day 29

  2. Percentage of Participants with Antigen 1 Seroconversion Rate (SCR)

    Timeframe: Day 1 to Day 29

  3. Percentage of Participants with Antigen 1 Seroprotection Rate (SPR)

    Timeframe: At Day 1 and Day 29

  4. Geometric Mean Increase (GMI) of Antigen 1 Titer

    Timeframe: Day 1 to Day 29

  5. GMT Of Antigen 2 Titer

    Timeframe: At Day 29

  6. Percentage of Participants with Antigen 2 SCR

    Timeframe: Day 1 to Day 29

  7. GMI of Antigen 2 Titer

    Timeframe: Day 1 to Day 29

  8. GMT ratio of serum neutralization titers against pseudovirus bearing spike from SARS-CoV-2 vaccine matched variant(s)

    Timeframe: At Day 29

  9. Percentage of participants with seroresponse of neutralization titers against pseudovirus bearing spike from SARS-CoV-2 vaccine matched variant(s)

    Timeframe: Day 1 to Day 29

  10. GMI of neutralization titers against pseudovirus bearing spike from SARS-CoV-2 vaccine matched variant(s)

    Timeframe: Day 1 to Day 29

Sources for outcomes
clinicaltrials.gov

Sex
All
Age groups
Older adults
Minimum age
65 Years
Maximum age
85 Years
Healthy volunteers
No

  1. Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol independently or with the assistance of the caregiver.
  2. Informed consent obtained from the participant prior to performance of any study-specific procedure.
  3. A male or female 65 to 85 years of age (YoA) (inclusive) at the time of screening.
  4. Healthy participants or medically stable patients as established by medical history and clinical examination.
  5. Other protocol-defined inclusion criteria may apply.

  1. Any clinically significant laboratory abnormality.
  2. History of symptomatic influenza/ SARS-CoV-2 infection confirmed by local health authority-approved testing methods within 180 days (for influenza) or 90 days (SARS-CoV-2 infection) prior to study intervention administration.
  3. History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine.
  4. Current or past malignancy, unless completely resolved without clinically significant sequelae (e.g., no evidence of disease following successful treatment of basal cell carcinoma cases are allowed) for >5 years.
  5. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  6. History of or current suspicion of myocarditis or pericarditis (including following administration of an mRNA vaccine); or idiopathic cardiomyopathy, or presence of any medical condition that increases the risk of myocarditis or pericarditis, including cocaine abuse, cardiomyopathy, endomyocardial fibrosis, hypereosinophilic syndrome, hypersensitivity myocarditis, eosinophilic granulomatosis with polyangiitis and persistent myocardial infection.
  7. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
  8. Acute or unstable chronic conditions, clinically significant pulmonary, cardiovascular, or renal functional abnormality, as determined by physical examination and/or laboratory screening tests.
  9. History of hypersensitivity or allergic reaction to any previous influenza or COVID-19 vaccine.
  10. History of hypersensitivity or allergic reaction to any previous mRNA vaccine.
  11. Administration of any influenza vaccine within 181 days before the study intervention administration (Day -180 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
  12. Administration of a SARS-CoV-2 antigen-containing vaccine in the period starting 91 days before the study intervention administration (Day -90 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
  13. Administration of any mRNA-based vaccine in the period starting 29 days before the study intervention administration (Day -28 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
  14. Administration of any other vaccine not foreseen by the study protocol in the period starting 29 days (Day -28 to Day 1) before the study intervention administration or planned administration within 28 days (Day 29) after the study intervention administration.
  15. Other protocol-defined exclusion criteria may apply.
Sources for eligibility
clinicaltrials.gov

  • GSK Investigational SiteAnniston, United StatesRecruiting
  • GSK Investigational SiteLittle Rock, United StatesRecruiting
  • GSK Investigational SiteFair Oaks, United StatesRecruiting
  • GSK Investigational SiteSan Diego, United StatesRecruiting
  • GSK Investigational SiteMiami, United StatesRecruiting
  • GSK Investigational SiteMiami Lakes, United StatesRecruiting
  • GSK Investigational SiteWest Palm Beach, United StatesRecruiting
  • GSK Investigational SiteStockbridge, United StatesRecruiting
  • GSK Investigational SiteAustin, United StatesRecruiting
  • GSK Investigational SiteCharlottesville, United StatesRecruiting
  • GSK Investigational SiteNewport News, United StatesRecruiting
  • GSK Investigational SiteSeattle, United StatesRecruiting
Sources for sites
clinicaltrials.gov

Related records

Drugs (2)

Lead sponsors (1)

Conditions (2)

Targets (1)